Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On December 14, 2020 $AVXL released this: https://www.anavex.com/post/anavex-life-sciences-announces-anavex-2-73-meets-primary-and-secondary-endpoints-in-clinical-trial
Anavex Life Sciences Announces ANAVEX®2-73 Meets Primary and Secondary Endpoints in Clinical Trial
Primary safety, pharmacokinetics and secondary efficacy endpoints met, with consistent improvements in RSBQ Total scores and CGI-I
Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms and correlated with changes in biomarker (glutamate) of disease pathology
Key milestone met to advance regulatory approval pathway for adult patients with Rett syndrome
$CYDY challenges the 52 week low.
The situation will remain the same for next week as the sales pitch is rapidly losing effectiveness, but it is helping the toxic lenders and warrant holders unload discounted shares into the volume.
Way too late for that, leronlimab needs $CYDY to go through a good old OTC "Wash, Rinse, Repeat"
CYDY needs a major overhaul in leadership. There has been so much the investors have been misled on by Nader and Kelly.
© 2021 InvestorsHub.com, Inc.
I didn't follow the dose schedule excuses, but was Dr. Jacob the cause or the solution?
March 13,2020 : "Jacob P. Lalezari, M.D. as Interim Chief Medical Officer. Dr. Lalezari is currently leading CytoDyn’s immediate preparations to initiate a coronavirus (COVID-19) clinical trial and the Company will file a modified trial protocol on Friday, March 13."
Great, but it's the long share selling warrant holders and toxic lenders that are executing the sell pressure.
Personally I like this news as I thought working the daily "Regulation SHO" report back in my day was simply regulatory busy work with zero net effect at enforcement of the spirit of the rule. But I digress.
He wisely never owned $CYDY.
Lalezari looks nervous. He would know more about the inner workings of CYDY than us rando bloggers. Hes the proverbial canary in the coal mine. His only source of income and he writes a letter begging.
ps-Quest Research receives financial support for studies with leronlimab on HIV and cancer. I
don’t own/never owned any stock or have any other financial stake in CytoDyn.
Short interest is now down to 6.3% of shares outstanding and is historically low for $AVXL.
This is not a squeezable percentage and IMO increases in $AVXL's price will be from "organic" market demand.
I know bookrunners, toxic lenders and OTC "chop shops" get paid whenever volume is created.
A simple Google search found Jacob Lalezari.
https://www.questclinical.com/dr-jay
Maybe the legal entity search didn't include all "dba", doing business as names.
It appears he had ONE job, and that one job was to being paid to produce reports for $CYDY.
https://www.questclinical.com/study-participation
Thinking he is as a reliable source is laughable!!!
Tomorrow will bring in a new 52 week low.
2 PR's and nothing, the sales pitch is rapidly losing effectiveness, but it is helping the toxic lenders and warrant holders unload cheap shares onto remaining retail dreamers.
Dr. Jay Lalezari's employer receives funds for his salary from $CYDY... quite the conflict of interest to be objective.
Quest Research receives financial support for studies with leronlimab on HIV and cancer. I don’t own/never owned any stock or have any other financial stake in CytoDyn.
Trading today looks like the book runners had a hard time controlling the sell off.
Wonder what's left on the pump story agenda?
Better luck tomorrow.
Warrant holders and owners of discounted stock made some nice profits selling into today's pump story.
"who chases a worldwide pandemic for two years in 4 trials and can't enroll them"
The same type of company that pumps acceptance to have a meeting to further ask for permission to underpower the study. That way the company can have an excuse for the inevitable failure and scapegoat anything besides itself.
Unrivaled Brands Announces Grand Opening of People’s Downtown Los Angeles Location
https://ir.unrivaledbrands.com/news-events/press-releases/detail/321/unrivaled-brands-announces-grand-opening-of-peoples
Special operatives at the primary broker are working hard to convince shareholders not to sell.
Paulson and crew have a rough job I'm sure.
Company CRO asks for permission to underpower study so company can have an excuse for the inevitable failure.
ANVISA will probably deny the request, as it's simply bad science to deliberately underpower a study.
ANVISA has authorized CytoDyn to submit the requested changes.
Most pathetic attempt at a pump to date!
....received its agreement to modify the CD16 trial for critically ill COVID-19 patients. ANVISA has authorized CytoDyn to submit the requested changes.
You are correct in that the shares were in exchange from the revenue producing mergers.
Nobody got something for nothing. I would have pointed it out.
The darkness is $CYDY being sucked into an OTC black hole, zero light will escape.
We are in the darkness now but not for much longer
yet $CYDY has a bum rush on the bid as an opener.
Market is buying, not selling.
Folks are selling CYDY.
I was a registered principal under both broker/dealer (suitability) and investment advisor (fiduciary) rules and guidelines and wrote internal documents to reconcile the 2 disciplines.
I've played both defence and offence versus and allied with FINRA and the SEC over my past career.
Good luck and I hope people are using their $CYDY tax losses well against other gains.
Make sure suitability or fiduciary notes are maintained and/or hope all the trades were marked "unsolicited".
Besides a slap on the wrist and a note on the brokercheck is the only penalty for most. White collar crime is easy and worth the risk for many so "have at it".
Any licensed representative who has promoted $CYDY to clients should be taken to arbitration.
Fundamentally per the 10-K $CYDY is worthless, but OTC markets are all about marketability of bullshit and $CYDY is good at selling worthless stock to OTC level gamblers.
I'm holding off on calling for the $0.75 level right now because $1 level has technical support.
That said yes, $CYDY is definitely going lower as warrant holders and discounted shareholders unload before they lose out.
Nader looked like a pure con man in that video. LOL!!!
A very reptilian Nadar performance. Anyone who has watched NP perform in these videos by now can tell the lies from the half-truths.
Pennyland!!!
Wait what? There is a problem with the vials, the largest asset on the books?
PIPE running special ops entities are probably busy lately trying to slow down the tide of warrant and discounted stock sellers.
Gonna be a tough sell for this tranche:
https://www.sec.gov/Archives/edgar/data/1175680/000120919121067720/xslFormDX01/primary_doc.xml
Proactive is simply a paid platform hosting infomercials for fees and/or discounted stock.
It's all good as they use proper disclaimers...
If leronlimab has true potential, it will not be realized under the entity that is $CYDY due to the many red flags pointed out here.
Watch the trials and in the meantime invest your capital elsewhere.
Discounted stock and warrant holders have been steadily making their exits.
So far it's been nice and orderly, but that can change fast as retail will be bailing on OTC tickers. Firms like Schwab are now charging fees and commission on OTC.
Lack of free trading takes the fun out of it.
Ouch new low.
Maintain an orderly exit bookrunners.... play nice, no cutsies.
PIPE runners are not concerned with such matters.
That part of the industry operates on a very different rulebook from those with Series 66 licenses. Or I should say, within the loopholes and exploited weakness of the rules.
So true in that $CYDY is rookie broker test question.
That's unfortunate.
I operated as a fiduciary in a broker dealer environment.
My clients rarely had to check up on their investments.
Got to run, My mother is on the phone and always asks how her CYDY is developing.
WOW, simply fascinating distractionary topic ....LOL!!!
Brokerage operations is so boring and irrelevant.
Any "special operations" on that list?
That narrative was "debunked" or at least corrected.
As long as $CYDY has entities to promote and maintain sales volume to disburse the deep discounted shares and warrants under regulation D, bankruptcy can be staved off. How long depends on how well the pump narrative can sell shares.
Wait a minute you said we were 100% bankrupt to start October last time I checked we are not just more and more false narratives
Indeed those personal attacks about NP are funny.
Such material I take under advisement to the character of the management, but I care little about that stuff in my commentary.
My interest is in watching the system extract wealth from one tier of "investor" to another under the guise of equity investing.
The only thing worth LOL’ing about here are the impotent attacks on Cytodyn. Can’t wait to hear about NP’s meaningless felony from decades ago. What was it? Armed robbery? Oh no, just a bounced $100 check you say? LOL x 100